PharmaCyte Biotech (PMCB) Interest & Investment Income (2013 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Interest & Investment Income of $78503.0 for Q2 2026, down 65.85% year-over-year from $229875.0 in Q2 2025, and down 65.97% quarter-over-quarter from $230668.0 in Q1 2026.
PharmaCyte Biotech (PMCB) Interest & Investment Income (2013 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Interest & Investment Income for 9 consecutive years, with $78503.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest & Investment Income fell 65.85% year-over-year to $78503.0; the TTM figure through Apr 2026 stood at $733351.0 (down 48.19% YoY), while the FY2026 annual figure was $733351.0, down 48.19% from the prior year.
- Interest & Investment Income slipped to $78503.0 in Q2 2026 per PMCB's latest filing, from $230668.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $894181.0 in Q4 2023 and bottomed at $45459.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $423180.9 across 5 years, with a median of $319127.0 in 2024.
- Annual changes were most pronounced in 2022 — Interest & Investment Income soared 1614.24% — and 2025, when it tumbled 71.0%.
- PharmaCyte Biotech's Interest & Investment Income stood at $439171.0 in 2022, then soared by 103.61% to $894181.0 in 2023, then tumbled by 57.22% to $382562.0 in 2024, then plunged by 46.05% to $206387.0 in 2025, then plunged by 61.96% to $78503.0 in 2026.
- Business Quant data shows PMCB's Interest & Investment Income at $78503.0 in Q2 2026, $230668.0 in Q1 2026, and $206387.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | 78,503.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 78,503.00 |
| Jan 31, 2026 | 230,668.00 |
| Oct 31, 2025 | 206,387.00 |
| Jul 31, 2025 | 217,793.00 |
| Apr 30, 2025 | 229,875.00 |
| Jan 31, 2025 | 255,692.00 |
| Oct 31, 2024 | 382,562.00 |
| Jul 31, 2024 | 547,432.00 |
| Apr 30, 2024 | 747,098.00 |
| Jan 31, 2024 | 881,662.00 |
| Oct 31, 2023 | 894,181.00 |
| Jul 31, 2023 | 875,878.00 |
| Apr 30, 2023 | 722,937.00 |
| Jan 31, 2023 | 635,889.00 |
| Oct 31, 2022 | 439,171.00 |
| Jul 31, 2022 | 139,502.00 |
| Apr 30, 2022 | 86,567.00 |
| Jan 31, 2022 | 45,459.00 |
| Oct 31, 2021 | 25,619.00 |
| Jan 31, 2015 | 22.00 |